FORA Capital’s Relay Therapeutics RLAY Stock Holding History

FORA Capital’s Portfolio RLAY Stock Details RLAY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-1,010	Closed	-$37K	–	767
2021 Q2	$37K	Buy	+1,010	New	+$33.3K	0.01%	760

Other funds holding RLAY

SIAU

SB Investment Advisers (UK) London, United Kingdom $7.73B AUM 2.35% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

FORA Capital's RLAY Position: Q3 2021 in Review

FORA Capital sold out of Relay Therapeutics (RLAY) in Q3 2021, closing a stake of 1,010 shares — an estimated $37K sold.

FORA Capital first reported a position in RLAY in Q2 2021 and held it in 1 quarter. The position peaked at $37K in Q2 2021. 132 funds tracked by Wall St. Rank hold RLAY as of Q3 2021.

FORA Capital reported no remaining Relay Therapeutics position as of Q3 2021 after selling out during the quarter.
FORA Capital sold 1,010 Relay Therapeutics shares in Q3 2021, an estimated $37K.
FORA Capital first reported a position in Relay Therapeutics in Q2 2021 and held it in 1 quarter.
FORA Capital's Relay Therapeutics position peaked at $37K in Q2 2021.
132 funds tracked by Wall St. Rank held Relay Therapeutics as of Q3 2021.

Based on FORA Capital's 13F filing for Q3 2021, filed 15 Nov 2021.